Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts rate Arrowhead Pharmaceuticals “Moderate Buy,” with nine buys, three holds and one sell among 13 firms. The average 12-month price target is $97.33, above the reported share price of $87.65.
• Analyst outlook remains mixed: HC Wainwright maintained a $120 target and raised its long-term EPS forecast, while it also cut several near- and medium-term earnings estimates. Consensus still projects losses through the current year and fiscal 2027, with profitability expected later.
• Arrowhead’s latest quarter showed revenue growth of 171% year over year to $75.25 million, but the company missed EPS expectations, reporting a loss of $1.36 per share versus the anticipated $1.23 loss. Institutional investors own 62.61% of the stock, while an insider recently sold shares under a pre-arranged trading plan.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $97.3333.

ARWR has been the subject of several research reports. Morgan Stanley boosted their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. JPMorgan Chase & Co. increased their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They issued a "buy" rating and a $98.00 target price on the stock. Weiss Ratings cut Arrowhead Pharmaceuticals from a "hold (c-)" rating to a "sell (d-)" rating in a report on Wednesday, May 20th. Finally, Chardan Capital boosted their price target on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a "buy" rating in a research report on Wednesday, July 22nd.

Key Stories Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $120 price target, well above recent trading levels. The firm also raised its FY2030 EPS forecast to $5.42 from $4.64, suggesting analysts still expect substantial earnings growth from Arrowhead’s pipeline and commercialization prospects. Analysts Offer Insights on Healthcare Companies
• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to a loss of $3.45 from a loss of $3.75 and improved its Q4 2026 estimate to a loss of $1.35 from a loss of $1.51. These revisions point to somewhat better near-term results than previously expected.
• Neutral Sentiment: Arrowhead remains expected to report losses in FY2026 and FY2027, with consensus current-year EPS at a loss of $3.40. HC Wainwright’s forecast assumes profitability eventually emerges, including positive EPS in Q4 2027 and $5.42 EPS in FY2030.
• Negative Sentiment: HC Wainwright substantially reduced its EPS forecasts for FY2026, FY2027, FY2028 and FY2029, as well as Q1–Q4 2027. The FY2027 estimate was cut to a loss of $4.61 from $3.35, while the FY2028 estimate moved to a loss of $4.14 from $3.12. These revisions indicate greater expected spending or delayed revenue and could limit the stock’s gains.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director directly owned 52,012 shares of the company's stock, valued at $3,998,682.56. The trade was a 5.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is currently owned by company insiders.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ARWR. BlackRock Inc. purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $1,208,838,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Arrowhead Pharmaceuticals by 3,142.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company's stock valued at $71,797,000 after acquiring an additional 2,017,489 shares in the last quarter. Norges Bank purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $113,159,000. Fred Alger Management LLC boosted its position in Arrowhead Pharmaceuticals by 497.4% during the 4th quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company's stock worth $121,693,000 after purchasing an additional 1,526,164 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Arrowhead Pharmaceuticals in the 1st quarter valued at $64,988,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $87.65 on Friday. The company's 50 day simple moving average is $79.97 and its 200 day simple moving average is $71.43. The company has a debt-to-equity ratio of 1.77, a quick ratio of 6.23 and a current ratio of 5.90. Arrowhead Pharmaceuticals has a 1 year low of $15.01 and a 1 year high of $95.49. The stock has a market capitalization of $12.35 billion, a PE ratio of -38.96 and a beta of 1.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The business's revenue for the quarter was up 171.0% on a year-over-year basis. During the same period last year, the company posted ($1.26) EPS. As a group, sell-side analysts expect that Arrowhead Pharmaceuticals will post -3.46 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source